Melanoma Trial

Advanced, BRAFV600-Mutated

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients with Stage III-IV BRAFV600 Melanoma

OR

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing), A Phase III Trial

 

Physician and Research Staff Educational Material

This material is intended for promotional use among health care professionals and is NOT intended for use as patient educational material.

    • Pocket Reference Card: trial schema, study objectives, and eligibility requirements on a pocket-sized card for easy reference when consulting with patients in the office or on rounds.
    • Physician Fact Sheet: schema, study objectives, eligibility criteria, and other key information about the study.
    • Site Process Summary: schema, objectives, and details about how your site can participate.

Information and Assistance from the National Cancer Institute

    • Locations and other information
    • Trained information specialists at the NCI are available to answer cancer-related questions from patients, family members or friends, health care providers, and researchers. Visit the NCI’s Cancer Information Service webpage for contact instructions, including telephone, live chat, email, and mail.

ClinicalTrials.gov ID: NCT02224781

Return to Home Page | Review Other Active Trials